Treatment‐associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?
- 20 May 2024
- journal article
- editorial
- Published by Wiley in American Journal of Hematology
- Vol. 99 (8) , 1459-1461
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choicesAmerican Journal of Hematology, 2024
- Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatmentLeukemia, 2023
- Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasmsAmerican Journal of Hematology, 2023
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyThe Lancet Haematology, 2020
- Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance ReviewClinical Lymphoma Myeloma and Leukemia, 2020
- Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or youngerAmerican Journal of Hematology, 2018
- Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosisLeukemia, 2013
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Reporting Results From Chemotherapy TrialsJAMA, 1984